Limited Field Radiotherapy Concomitant with Cisplatin/Etoposide Followed by Consolidation Docetaxel for the Treatment of Inoperable Stage III Non-Small Cell Lung Cancer.

Purpose: To evaluate the efficacy and outcome of concomitant cisplatin/etoposide and limited field irradiation followed by consolidation docetaxel in patients with locally advanced non small cell lung cancer (NSCLC).

Patients And Methods: This is a prospective phase II study that included 32 patients with locally advanced stage III NSCLC who presented to the Radiation Oncology and Chest Departments- Ain Shams University hospitals, and Sohag Cancer Center between May 2004 and August 2006. Eligible patients were treated first with two cycles of cisplatin 50mg/m2/day on days 1, 8, 29 and 36 and etoposide 50mg/m2/day on days 1-5 and 29-33 concomitant with conventionally fractionated radiation (66Gy in 2Gy fractions) to the gross primary disease and regionally involved lymph nodes followed by 3 cycles of consolidation single agent docetaxel, 75mg/m2/3 weeks.